We reasoned that if high expression of AURKA/B contribute to therapy resistance in p53 WT NSCLC cells, then inhibition of AURKA/B would sensitize the cells to therapy and this would occur in a manner that is at least partially p53-dependent. Here, AURKA is linked to non-small cell lung carcinoma.